Intelligence · Patents
Patents expiring in 2044
Annual patent cliff calendar for 2044 — US pharmaceutical patents by expiration date.
- Patents
- 1,766
Quick answer
1,766 indexed pharmaceutical patents have expiration dates in 2044. Browse by soonest expiry with links to assignee companies and related drugs.
-
US 11918638
Recombinant respiratory syncytial virus strains comprising NS1 and NS2 gene shifts
granted -
US 11919965
Methods of treating multiple myeloma with bispecific anti-BCMA x anti-CD3 antibodies
granted -
US 11918639
Methods and compositions for inducing protective immunity against filovirus infection
granted -
US 11918688
Treatment of hip pain with sustained-release liposomal anesthetic compositions
granted -
US 11918686
Lipid bilayer coated mesoporous silica nanoparticles with a high loading capacity for one or more anticancer agents
granted -
US 11919880
HCV protease inhibitors
granted -
US 11918594
Multi-substituent psilocybin derivatives and methods of using
granted -
US 11918627
Dosage regimen for inhaled vasoactive intestinal polypeptide
granted -
US 11919901
Inhibitors of the menin-MLL interaction
granted -
US 11918560
Serine protease inhibitor for treating coronavirus infection
granted -
US 11919910
Spiropyrrolidine derived antiviral agents
granted -
US 11918565
Treatment of post-operative pain via sciatic nerve block with sustained-release liposomal anesthetic compositions
granted -
US 11918551
Methods of treating seizure disorders and Prader-Willi syndrome
granted -
US 11918620
Traditional Chinese medicine composition, and preparation method therefor and application thereof
granted -
US 11920132
Oligonucleotide therapy for Leber congenital amaurosis
granted -
US 11918563
Methods and compositions for treatment of epileptic disorders
granted -
US 11918556
Treatment of circadian rhythm disorders
granted -
US 11918578
Methods for treating cholestasis
granted -
US 11919896
[1,2,4]triazolo[1,5-a]pyridine compound as JAK inhibitor and use thereof
granted -
US 11918571
Compounds and their methods of use
granted -
US 11918612
Synergistic bacterial compositions and methods of production and use thereof
granted -
US 11918633
Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating adolescent subjects
granted -
US 11918568
Fused ring compound having urea structure
granted -
US 11918622
Ready-to-use bivalirudin compositions
granted -
US 11918642
HIV vaccination compositions comprising vaccinia VLPS and plant-produced VLPS presenting HIV antigens
granted -
US 11918557
Treatment of circadian rhythm disorders
granted -
US 11919887
Substituted tetrahydrofurans as modulators of sodium channels
granted -
US 11919868
Heterocyclic compounds and related methods
granted -
US 11919937
T cell receptors for immunotherapy
granted -
US 11919888
Neprilysin inhibitors
granted -
US 11919836
Prodrugs of fencamfamine
granted -
US 11919915
Compounds and methods useful for stabilizing phenylalanine hydroxylase mutations
granted -
US 11919927
Prefusion-stabilized hMPV F proteins
granted -
US 11920134
Compositions and methods for inhibiting expression of RRM2 genes
granted -
US 11919972
Peptide libraries with non-canonical amino acids
granted -
US 11920169
Compositions for linking DNA-binding domains and cleavage domains
granted -
US 11919963
CD123-binding polypeptides and uses thereof
granted -
US 11919933
Use of MYOG gene as target in preparation of drug for treating cardiomyocyte apoptosis-associated cardiovascular disease
granted -
US 11920139
Regulated expression of antigen and/or regulated attenuation to enhance vaccine immunogenicity and/or safety
granted -
US 11918770
Implants for localized drug delivery and methods of use thereof
granted -
CA 3266054
COMPOSÉS DE N-MÉTHYL-4-(QUINOLIN-2-YL)PYRIDIN-2-AMINE
granted -
US 11926632
Methods and compounds for restoring mutant p53 function
granted -
US 11926584
Methods of making bempedoic acid and compositions of the same
granted -
US 11925649
Treatments for diabetic neuropathy
granted -
US 11925663
Methods of managing tumor flare in adoptive immunotherapy
granted -
US 11926625
HPK1 antagonists and uses thereof
granted -
US 11925629
Heterocyclic inhibitors of ERK1 and ERK2 and their use in the treatment of cancer
granted -
US 11925664
Intracellular genomic transplant and methods of therapy
granted
Frequently asked questions
How many pharma patents expire in 2044?
1,766 published patents in our USPTO index have expiration dates falling in calendar year 2044.